MentalHealthDaily

Abnormal Glutamate Biomarkers in ADHD: CDK5, MAP2, GKAP, PSD95 (2023 Study)

by GLOOM

Attention-Deficit Hyperactivity Disorder (ADHD) is a complex neurodevelopmental condition that has puzzled researchers and clinicians for decades. Recent studies have begun to unravel the intricate relationship between ADHD and the glutamatergic system, a major neurotransmitter pathway in the brain. A newer study evaluated the roles of cyclin-dependent kinase 5 (CDK5), microtubule-associated protein-2 (MAP2), guanylate kinase-associated …

Symptom Provocation in Psychiatric Disorders: TMS, EEG, Neural Circuits for Personalized Treatment (2023 Review)

by GLOOM

Symptom provocation, a cornerstone of psychiatric research and therapy, offers a fascinating glimpse into the intricate relationship between brain activity and psychiatric symptoms. By deliberately triggering symptoms, researchers and clinicians can identify neurophysiological biomarkers and target them with personalized therapies, such as transcranial magnetic stimulation (TMS). This technique not only enhances our understanding of psychiatric …

Analyzing Serum Biomarkers to Predict Antidepressant Efficacy in Depression (2023 Study)

by GLOOM

Depression, a complex and often debilitating mental health condition, affects millions globally. Despite advances in psychiatric medicine, finding the right treatment remains a challenge for many. A recent comprehensive study, however, is shedding light on this issue by examining the role of serum biomarkers in predicting the effectiveness of antidepressant therapy. Highlights: Innovative Approach: This …

Combo of Neuroimaging, Transcriptome, Epigenetics to Understand Gray Matter Abnormalities in Major Depression (2024 Study)

by GLOOM

Major depressive disorder (MDD) affects millions worldwide, yet its underlying causes remain largely enigmatic. A new study integrated neuroimaging, transcriptomic, and epigenetic data to better understand the genetic underpinnings of MDD. This comprehensive approach revealed a complex interplay between brain structure, gene expression, and DNA methylation, offering new insights into this debilitating condition. Highlights: Integrative …

Biomarkers in Major Depression: Interleukin-33 (IL-33) & Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) (2024 Study)

by GLOOM

Major depressive disorder (MDD) is a complex mental health condition that significantly impacts individuals’ lives globally. A recent study evaluates the biological underpinnings of this disorder, focusing on two specific biomarkers: interleukin-33 (IL-33) and mesencephalic astrocyte-derived neurotrophic factor (MANF). These findings could pave the way for new diagnostic and treatment strategies. Highlights: Major depressive disorder …

MicroRNA Biomarkers May Help Diagnose Schizophrenia

by GLOOM

Schizophrenia (SZ) is a complex psychiatric disorder characterized by a myriad of symptoms, typically divided into positive, negative, and cognitive categories. Despite the prevalence and severity of this condition, current diagnostic methods are largely based on subjective clinical interviews and observations, leading to potential misdiagnosis and delayed treatment. Recent studies have focused on microRNAs (miRNAs) …

Eye Tracking Technology for Rapid Depression Diagnosis in Young Adults

by GLOOM

Researchers have proposed a novel eye tracking method to rapidly screen for depression risk in young adults. This intelligent approach analyzes emotional perception deficits through objective eye movement biomarkers. Initial findings suggest promise for large-scale, low-cost depression screening without specialized doctors. Key Facts: The “eye movement emotional perception evaluation paradigm” extracts digital biomarkers related to …